

FEB 06 1997

DL-020697-01

Norman Steider, President
Memorial Hospital of Michigan City
Fifth and Pine Streets
Michigan City, IN 46360

Dear Mr. Steider:

It has come to our attention that Amendment Number 15 to License No. 13-18847-01 issued on February 20, 1996 contained an error.

Enclosed is a corrected copy reflecting Subitem 5. noted to be in error. We apologize for any inconvenience this may have caused you.

Sincerely,

Original Signed By
Gidget Watson
Nuclear Materials Licensing Branch

License No. 13-18847-01
Docket No. 030-14256

Enclosure: Corrected Copy of
Amendment No. 15

DOCUMENT NAME: M:03014256.CC7

To receive a copy of this document, indicate in the box: "C" = Copy without enclosures "E" = Copy with enclosures "N" = No copy

NAME	DNM/AM								
NAME	GWatson:bri								
DATE	02/05/1996								

OFFICIAL RECORD COPY

MATERIALS LICENSE

CORRECTED COPY

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purposes, and at the places, designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with application dated
April 28, 1995License Number 13-18847-01 is renewed in
its entirety to read as follows:

1 Memorial Hospital of Michigan City

2 Fifth and Pine Streets
Michigan City, IN 46360

4 Expiration Date February 28, 2001

5 Docket or
Reference No 030-142566 Byproduct, Source, and/or
Special Nuclear Material7 Chemical and/or Physical
Form8 Maximum Amount that Licensee
May Possess at Any One Time
Under This License

- | | | |
|---|---|---|
| A. Any byproduct material identified in 10 CFR 35.100 | A. Any radiopharmaceutical identified in 10 CFR 35.100 | A. As needed |
| B. Any byproduct material identified in 10 CFR 35.200 | B. Any radiopharmaceutical identified in 10 CFR 35.200 | B. As needed |
| C. Any byproduct material identified in 10 CFR 35.300 | C. Any radiopharmaceutical identified in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy) | C. As needed (not to exceed 1 curie of I 131) |
| D. Any byproduct material identified in 10 CFR 31.11 | D. Prepackaged Kits | D. As needed |

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300 (excluding iodine 131 for thyroid carcinoma therapy).
- D. In vitro studies.

9702260038 970205
PDR ADOCK 03014256
C PDR

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

13-18847-01

Docket or Reference Number

030-18847-01

Amendment No. 15

CORRECTED COPY

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at Memorial Hospital of Michigan City, Fifth and Pine Streets, Michigan City, IN, 46360-3330.
11. Radiation Safety Officer: R. S. Plank, M.D.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|-----------------------------|---|
| A. R. S. Plank, M.D. | For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| B. Windham Bremer, M.D. | For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| C. Marco John DiBiase, M.D. | For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| D. Robert E. McBride, M.D. | For material in 10 CFR 35.100 and 31.11. |
| E. Thomas R. Roberts, M.D. | For material in 10 CFR 35.100 and 31.11. |
| F. George A. Azar, M.D. | For material in 10 CFR 35.100 and 31.11. |
| G. Gregory Gates, M.D. | For material in 10 CFR 35.100 and 31.11. |
| H. Dean H. Lauer, M.D. | For material in 10 CFR 35.100 and 31.11. |
| I. Margaret J. Milos, M.D. | For material in 10 CFR 35.100, 35.200 and 35.300 (excluding iodine 131 for thyroid carcinoma). |
| J. Charles Trahm, M.D. | For material in 10 CFR 35.200 (excluding xenon-133 and aerosols). |
| K. G. David Beiser, M.D. | For material in 10 CFR 35.100, 35.200 and 31.11. |

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

13-18847-01

Docket or Reference Number

030-18847-01

Amendment No. 15

CORRECTED COPY

12. (Continued)

Authorized UsersMaterial and Use

L. Mary Sheer-Williams, M.D.

For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

M. Sridhar R. Mothkur, M.D.

For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

N. Richard Dobben, M.D.

For material in 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy) and 31.11.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated April 28, 1995; and
B. Letter dated March 23, 1990 (with attachments)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

February 5, 1997

By


Nuclear Materials Licensing Branch, Region III

COPY